Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tobemstomig plus platinum-based chemotherapy vs pembrolizumab plus platinum-based chemotherapy in first-line advanced NSCLC
2023-505211-21-00Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of tobemstomig in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Roche. Primary endpoints: Progression-free survival (PFS) after randomization and Objective response rate (ORR). Started Mar 2024; status: completed.
02
Drugs
tobemstomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-505211-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505211-21-00.